Immunome, Inc. (IMNM)
NASDAQ: IMNM · IEX Real-Time Price · USD
11.70
-0.50 (-4.10%)
At close: Jul 2, 2024, 4:00 PM
11.96
+0.26 (2.22%)
After-hours: Jul 2, 2024, 6:27 PM EDT
Immunome Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Immunome stock have an average target of 29.75, with a low estimate of 24 and a high estimate of 35. The average target predicts an increase of 154.27% from the current stock price of 11.70.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 31, 2024.
Analyst Ratings
The average analyst rating for Immunome stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Initiates $27 | Buy | Initiates | $27 | +130.77% | May 31, 2024 |
| JP Morgan | JP Morgan | Buy Initiates $24 | Buy | Initiates | $24 | +105.13% | Apr 30, 2024 |
| Guggenheim | Guggenheim | Strong Buy Initiates $35 | Strong Buy | Initiates | $35 | +199.15% | Apr 15, 2024 |
| Wedbush | Wedbush | Buy Maintains $27 → $33 | Buy | Maintains | $27 → $33 | +182.05% | Apr 1, 2024 |
| Wedbush | Wedbush | Buy Maintains $12 → $19 | Buy | Maintains | $12 → $19 | +62.39% | Jan 23, 2024 |
Financial Forecast
Revenue This Year
7.15M
from 14.02M
Decreased by -49.03%
Revenue Next Year
816.00K
from 7.15M
Decreased by -88.58%
EPS This Year
-3.67
from -5.38
EPS Next Year
-2.69
from -3.67
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 16.8M | 4.2M | 29.9M | 161.2M | 353.9M |
| Avg | 7.1M | 816,000 | 15.0M | 69.9M | 170.8M |
| Low | 980,000 | n/a | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 19.8% | -41.2% | 3,567.3% | 971.6% | 406.6% |
| Avg | -49.0% | -88.6% | 1,743.3% | 364.4% | 144.6% |
| Low | -93.0% | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.08 | -2.02 | -2.57 | -2.16 | -0.12 |
| Avg | -3.67 | -2.69 | -3.50 | -2.22 | -0.11 |
| Low | -3.79 | -3.80 | -4.66 | -2.24 | -0.11 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.